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Reduction of insulin and triglycerides delays glomerulosclerosis in
obese Zucker rats. To evaluate the effect of insulin and/or triglycerides on
the pathogenesis of glomerulosclerosis, acarbose (BAYg542I), an inhibi-
tor of intestinal a-glucosidases, was administered as a dietary admix (40
mg/100 g chow) to Zucker obese rats (ZOA), from 1.5 months until
sacrifice at 1.5, 5, 8, 10 and 15 months. Obese (ZO) and lean (ZL) rats
served as controls. Despite a similar food intake, ZOA weighed less than
ZO at all ages. Acarbose reduced serum triglycerides at all ages, and
insulin until 10 months. Glycemia remained normal in all groups. Protein-
uria developed with age and to a greater degree in ZO than in ZOA rats.
In ZL, a faint proteinuria appeared only in the oldest animals. Glomeru-
losclerosis, tubular and interstitial lesions rapidly affected ZO kidneys.
These lesions were reduced in ZOA until 10 months. Acarbose did not
modify the hypertrophy of the glomeruli that developed after three
months, but slowed down the expansion of the mesangial domain seen in
ZO. Thus, by reducing the amount of ingested glucose, acarhose yielded
a normal glycemia with a lesser production of insulin and reduced renal
impairment. Therefore, insulin could be a key factor involved in the
pathogenesis of glomerulosclerosis, either directly or through a control of
triglyceride concentrations.
Among several metabolic and hormonal disorders associated
with obesity and diabetes, hyperglycemia, hyperinsulinemia, insu-
lin resistance and abnormal composition and levels of circulating
lipoproteins are considered as risk factors for atherosclerosis and
glomerulosclerosis [1—41. Genetically obese Zucker rats (faif a)
develop hyperlipidemia and hyperinsulinemia at an early age [5;
reviewed in 6], and suffer from mild glucose intolerance and
peripheral insulin resistance similar to that found in humans with
Type II diabetes [7]. These rats serve as appropriate experimental
models for massive obesity seen in humans. These metabolic
abnormalities, as well as an early, moderate influx of macrophages
[8] precede the development of proteinuria, diffuse glomerulo-
sclerosis and focal and segmental glomerular hyalinosis [5, 8, 9]
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(FSGH, often called focal and segmental glomerulosclerosis [10,
11]). Lean littermates have normal serum lipids and insulin [121,
and normal renal structure and function [8, 13]. It is well known
that lipid supplemented diets increase the incidence and severity
of glomerulosclerosis in animal models [14—16]. Conversely, diets
reducing hyperlipidemia reduce glomerular injury [15, 17—19].
However, little is known on the potential effects of a reduction of
insulin levels itself on the development of glomerulosclerosis and
renal insufficiency.
Acarbose (BAYg5421) is a potent, orally administered intesti-
nal cs-glucosidase inhibitor. By reversibly inibiting several carbo-
hydrate enzymes, acarbose delays the time course of sugar and
starch digestion and slows down the rate of glucose absorption
from the gut [20, 21]. Administration of acarbose as a dietary
admix was shown to improve glucose tolerance in obese Zucker
rats [22, 23]. We have therefore attempted to examine the
long-term effect of acarbose administration to obese and lean
Zucker rats on the development and progression of diffuse
glomerulosclerosis and FSGH lesions by analyzing the temporal
relationship between hyperlipidemia, hyperinsulinemia, changes
in glomerular structure, expansion of the glomerular tuft and
proteinuria. Our studies show that long-term acarbose treatment
significantly reduced hyperinsulinemia and hypertriglyceridemia,
and partly protected obese Zucker rats from renal insufficiency
and glomerulosclerosis.
METHODS
Animals
Sixty female lean (Fa/fa) and 120 obese (fa/fa) Zucker rats were
identified and selected at four weeks of age by visual examination
of inguinal fat deposit. They were raised under standard hus-
bandry conditions, had free access to water and were fed regular
laboratory chow ad libitum (diet 105; UAR, Villemoisson sur
Orge, France), supplemented with 10% (wt/wt) sucrose. Obese
rats were randomized and 60 rats received acarbose (BAY g5421)
added to the chow at a dose of 40 mg/lOU g food, from 1.5 months
until sacrifice. Body weights were followed twice a week and daily
food intakes measured once a month. Every month, animals were
housed individually in metabolic cages with free access to water,
and 24-hour urine samples were collected and frozen for protein
determination. At 1.5, 5, 8, 10 and 15 months of age, 8 to 12
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animals were removed from lean (ZL), obese (ZO) and obese
acarbose-treated (ZOA) groups and euthanized by decapitation.
Animal care complied with the Principles of Laboratory Animal
Care formulated by the National Society for Medical Research
and the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health publication 86-23, revised 1989;
authorization 00577, 1989, Paris, France).
Determination of blood pressure, plasma glucose, insulin and
lipids, and urine proteins
A week before sacrifice, conscious systemic blood pressure (BP)
was measured by a tail-cuff system (Ugo Basile Apelex, Varese,
Italia), except for 1.5-month-old animals for whom the apparatus
was not adapted. At the time of sacrifice, blood was collected into
tubes containing heparin as the anticoagulant for plasma lipid,
insulin and glucose assays. These samples were centrifuged and
aliquots of plasma were frozen and stored at —20°C. Plasma
lipids, triglycerides and total cholesterol were determined by the
enzymatic and colorimetric GPO-PAP and CHOD-PAP methods,
respectively (Boerhinger, Mannheim, Germany). Plasma insulin
was measured by radio-immunoassay (CIS, Gif sur Yvette,
France) with a rat insulin standard (Novo, Copenhagen, Den-
mark) and plasma glucose by colorimetry with peroxidase with
anhydre glucose as the standard. Proteinuria was determined
using the Coomassie Protein Assay Reagent with bovine serum
albumin as the standard (Pierce, Rockford, IL, USA).
Kidney structure
After sacrifice of the animals, kidneys were removed and
weighed. For light microscopy, transverse sections of the kidneys
at the hilus were directly frozen in liquid nitrogen, others were
fixed in alcoholic Bouin's solution, embedded in paraffin, sec-
tioned (4 jtm thick), and stained with Masson's trichrome or silver
methenamine, according to routine histological staining. For
electron microscopy, small samples of the kidney cortex were fixed
in 2% glutaraldehyde/0.2 M cacodylate buffer, dehydrated in
acetone and embedded in Glucidether 100 (Merck, Darmstadt,
Germany). For immunofluorescence labeling, frozen sections
were incubated for 60 minutes at room temperature (RT) with an
IgG fraction of polyclonal rabbit antibody directed against rat
IgGs (1:20; Dako Corporation, Copenhagen, Denmark), albumin
(1:20), C3 (1:5) or fibrinogen (1:20; Nordic Diagnostics, Berchem,
The Netherlands), washed in Tris-huffered saline and then incu-
bated for 60 minutes at room temperature (RT) with a fluores-
cein-conjugated swine anti-rabbit antibody (Dako).
Masson's trichrome stained sections were examined and scored
for glomerular and tubulointerstial lesions according to a grading
scale: 0, no lesion; 1, lesion of minimal severity involving tubular
dilation and faint FSGH; 2, mild severity FSGH, tubular lesions
with the presence of proteinaceous casts, mild interstitial fibrosis
with inflammatory cells and mild FSGH; 3, same lesions with
moderate severity; 4, more severe lesions involving all structures.
The percentage of glomeruli having FSGH lesions was deter-
mined for each tissue specimen with at least 100 glomeruli
surveyed in each section.
Morphometric measurements
The thickness of the glomerular basement membrane (GBM)
was evaluated from electron micrographs enlarged to a magnifi-
cation of 42,000. Only capillaries in which the plasma membrane
of the foot processes was clearly visible along the basement
membrane were considered to assure that the section was per-
pendicular to the GBM. The width of the lamina densa was
measured with a ruler oriented at right angle to the GBM, in areas
not directly contiguous to the mesangial matrix. At least three
glomeruli were examined from each rat, with a minimum of five
capillary sections surveyed in each glomerulus. The exact magni-
fication of the image was calculated using diffraction grating
replica standard (Polaron Equipment, Watford, UK).
Morphometric determination of the different glomerular do-
mains and parameters was performed using an automated image-
analyzing system on transverse kidney sections processed with
silver methenamine staining that reveals the extracellular matri-
ces. The image-analyzing system was composed of a light micro-
scope (Nachet, Microvision, Evry, France), a black and white
video camera (Cohu, San Diego, CA, USA), an image-analysis
processor (NS-15000, Nachet), and a microcomputer to store the
data and pilot the processor using a personal program written in
C language. The image analysis processor, based on the principles
of mathematical morphology, digitizes microscopic images into
512 X 512 pixel images within 256 gray levels. The digitized
images were submitted to predefined transformation allowing
automatic measurements of selected glomerular morphometric
parameters [24]. The glomeruli were measured with a x25
objective, yielding a final calibration of 0.4219 rm/pixel. Any
variability in the staining intensity of the sections could be
corrected by calibrating the image according to the defined gray
levels. The glomerular parameters measured were: (1) total
glomerular surface area delimited by the internal edge of the
Bowman's capsule; (2) urinary space surface area; (3) cumulative
surface area of the capillary lumen sections; (4) glomerular tuft
surface area, defined by the total glomerular measurement minus
the urinary space; (5) mesangial surface area, defined by the
glomerular tuft measurement minus areas of the capillary lumens
and the glomerular capillary free walls. The total number of
glomeruli necessary to yield convergent data was established at 30
glomeruli per rat [24]. The observer, unaware of the code of the
sections, measured 30 glomeruli randomly over the depth of the
cortex on each kidney section. Glomeruli showing clear glomer-
ular tuft retraction or extensive FSGH were not measured, since
in these cases the differences between matrices, remnant capillary
lumen sections and urinary spaces were indistinguishable.
Statistical analysis
Results are expressed as means SEM. Statistical analysis was
carried out using two-way analysis of variance with age and
genotype or treatment as factors. Statistical significance was
achieved if P < 0.05. In cases of interaction between the factors,
one-factor analysis of variance was used at one level of the other
factor. Data were analyzed using the Statiew 4.0 software (Abac-
cus Concept Inc., Berkeley, CA, USA).
RESULTS
The age-related changes in body wt of the animals arc pre-
sented in Figure 1. All rats rapidly increased in weight during the
first four months of life. Thereafter, ZL rats stabilized in weight
whereas ZO and ZOA rats were still gaining weight, more in ZO
than in ZOA groups. An overall statistical analysis demonstrated
a significant difference between all groups. At 10 to 15 months,
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Fig. 1. Age-related changes in body weight (A) and in food intake (B) in
Zucker lean (ZL, •), obese (ZO, •) and acarbose-treated (ZOA, A) obese
rats. Despite similar food consumption, ZOA rats gained less weight than
ZO rats. The age and group effects on body weight were P < 0.05; the
group effect for food intake on ZL versus ZOIZOA rats was P < 0.05. The
number of animals comprised at least 21 rats in each group, except at 15
months when N = 18 and 7 in the ZO and ZOA groups, respectively.
body wts plateaued in the three groups, with ZO and ZOA body
wts of 2.1- and 1.9-fold ZL body wt, respectively. Daily food intake
per animal remained roughly constant with age in all groups,
significantly higher in ZO and ZOA than in ZL rats at all ages.
Despite their difference in weight gain, ZOA and ZO rats had
similar food consumption (Fig. 1). The cumulative weight of the
two kidneys increased with age in the three experimental groups.
They differed significantly from each other, except at 15 months
when ZO and ZOA kidneys had similar weights (Table 1). No
significant hypertrophy of the kidneys was observed as shown by
the kidney to body wt ratio. However, while the kidney weight
increased harmoniously in proportion to the body weight in lean
rats, it increased more slowly than the body weight in ZO and
ZOA rats, especially at the early ages (Table 1).
Mean systolic tail cuff blood pressure (Table 1) was higher in
ZO than in ZL rats and did not significantly change with age in
both groups. In young 5-month-old ZOA rats, acarbose signifi-
cantly reduced blood pressure to the value of ZL rats. This
hypotensive effect of acarbose disappeared later on.
Plasma levels of triglycerides and cholesterol (Table 2) were
significantly higher in the two obese groups than in lean rats at all
ages. Although triglycerides increased 1.5-fold and 2-fold in ZO
and ZOA rats, respectively, between 5 and 15 months, acarbose
significantly lowered (1.5-fold) triglyceridemia in ZOA as com-
pared to ZO rats. Cholesterolemia was always higher in obese ZO
and ZOA rats than in lean animals, but did not change on the
whole with age. However, acarbose significantly reduced plasma
cholesterol at 10 and 15 months. Plasma insulin levels (Table 2),
higher in both obese groups than in lean rats, plateaued at 5 and
10 months in ZO and ZL groups. They declined thereafter in ZO
but rose in ZL rats. Acarbose significantly reduced insulinemia by
a factor of 2 at 5 and 10 months. At 15 months acarbose was no
longer efficient and insulinemia reached the value seen in ZO rats
at 10 months. Glycemia remained normal in all groups (Table 2).
Proteinuria developed markedly in obese rats until 10 months,
more rapidly and more intensively in ZO than in ZOA rats, and
tended to stabilize thereafter (Fig. 2). In ZL rats, a faint protein-
uria appeared only in the oldest animals and, at 15 months,
remained 10-fold and 8-fold less than ZO and ZOA proteinuria,
respectively. All groups differed significantly at all ages.
Histopathological examination of the kidneys revealed that
focal and segmental glomerular hyalinosis (FSGH) as well as
tubular and interstitial lesions rapidly affected the kidneys of
obese rats (Fig. 3). Tubular lesions are characterized by a tubular
atrophy, a clarification of the tubular cells, cellular debris in the
lumen and the presence of tubular casts and cystic formations. In
close vicinity of damaged tubules and sclerosed glomeruli, mono-
nuclear cells invaded areas of interstitial fibrosis. The severity of
the overall glomerular, tubular and interstitial lesions was scored
for the different experimental groups (Table 3). It significantly
increased with age in all groups, but was more intensive and rapid
in the ZO than in the ZOA and ZL rats. In some glomeruli, the
glomerular tuft retracted. While in ZL rats this retraction was
infrequent and affected no more than 5% of the glomerular
population, it varied considerably from one animal to the other in
ZO and ZOA rats, and worsened with age in a similar manner in
the two obese groups, to affect 15 to 20% of the glomeruli at 15
months (Table 3). Ultrastructural examination revealed frequent
localized bulging of the visceral epithelial cells, in which numerous
droplets accumulated (Fig. 4). These structural changes forestall
the establishment of FSGH lesions: in certain localized areas,
podocyte foot processes progressively detached from the glomer-
ular basement membrane, concomitantly with an accumulation of
newly synthesized ECM components (Figs. 4 and 5). Afterwards,
podocytes degenerated and disappeared (Fig. 5). These areas,
with denuded parts of GBM, constituted foci of adherence with
the basement lamina of Bowman's capsule. Underlying capillaries
collapsed with a progressive disappearance of endocapillary cells
and a formation of hyalin and lipid deposits (Fig. 5).Therewas no
sign of FSGH in lean rat kidneys until eight months; at 10 to 15
months, FSGH was detectable and affected 1 to 2% of the
glomeruli (Table 3). On the contrary, the incidence of FSGH in
ZO rats was close to 4% at five months, and rapidly increased in
quantity and severity to affect 20% of the glomeruli at 15 months.
Acarbose reduced this incidence until 10 months where it was
almost twofold less than in ZO group. Thereafter, despite acar-
bose, the lesions worsened and FSGH frequency increased con-
siderably (Table 3).
Using fluorescent immunohistochemistry, C3 moieties were
commonly observed at all ages over the tubular basement mem-
branes. In old rats, they were also observed on foci of FSGH (not
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Table 1. Kidney weights and systemic blood pressures
Age
5 months 8 months 10 months 15 months
Two-kidney weight g
ZL
ZO
ZOA
1.572 0.039 (10)
2.449 0.053 (9)
1.977 0.075 (9)"'
1.621 0.097(11)
2.454 0.066 (12)
2.088 0.113 (12)""
1.884 0.07 (8)
3.804 1.392 (8)
2.696 0.216 (8)""
1.894 0.077 (10)"""
3.032 1.443 (12)""
3.281 0.449 (9)""
Two-kidney/100 g body weight
ZL 0.582 0.014 (10) 0.571 0.033 (11) 0.598 0.021 (8) 0.653 0.017 (10)""
ZO
ZOA
0.489 0.01 (9)
0.481 0.017 (9)'
0.426 0.012 (12)
0.469 0.024 (12)'
0.600 0.085 (8)
0.494 0.041 (8)
0.522 0.099 (12)
0.632 0.108 (9)
Systolic blood pressure mm Hg
ZL
ZO
ZOA
133.0 3.8 (10)
173.3 5.9 (9)
140.0 4.4 (9)"
130.4 5.8 (11)
177.1 5.9 (12)
163.7 5.2 (12)'
143.7 4.9 (8)
193.1 7.4 (8)
165.0 7.1 (8)""
139.4 3.3 (10)"'
170.4 8.0(12)"
181.2 9.8 (9)"'
Abbreviations are: ZL, Zucker lean rat; ZO, Zucker obese rat; ZOA, Zucker acarbose-treated obese rat. Numbers of rats are in parentheses.
Age effect, P < 0.05
"Overall group effect, ZL vs. ZO rats, P < 0.05
"Overall group effect, ZL vs. ZOA rats, P < 0.05
"Overall group effect, ZO vs. ZOA rats, P < 0.05
"ZOA vs. ZO, P < 0.05 at a given age
ZOA vs. ZL, P < 0.05 at a given age
Table 2. Plasma parameters
Age
5 months 10 months 15 months
0.71 0.07 (9)
4.32 0.40 (9)
2.01 0.39 (9)"'
0.42 0.02 (9)
0.96 0.05 (10)
1.01 0.2 (10)'
21.11 1.35 (6)
130.1 20.27 (9)
64.32 7.09 (10)""
1.37 0.19 (7)
1.12 0.09 (9)
1.15 0.16 (8)'
0.81 0.09 (7)
5.54 0.25 (7)
3.34 0.63 (8)""
0.40 0.04 (7)
0.95 0.09 (7)
0.74 0.09 (8)"'
27.56 3.00 (7)
127.90 19.25 (7)
69.40 9.85 (8)ef
1.41 0.19 (7)
1.34 0.11 (8)
1.39 0.08 (8)
0.94 0.18 (10)"'"
6.49 1.19(10)""'
4.3 0.81 (8)"""
0.35 0.03 (7)h.C
0.82 0.20 (6)
0.68 0.09 (8)""
75.75 (8).h.C
118.17 5.08 (12)d
123.20 2.52 (6)"""
ND
ND
ND
illustrated). Fibrinogen was always associated with areas of FSGH
(not shown). In aging rats, albumin accumulated in characteristic
droplets in podocytes, more in ZO than in ZOA rat kidneys.
Either no or very few albumin droplets were seen in lean rats (Fig.
6). Albumin was also observed in tubular reabsorption vacuoles
and in tubular casts (not illustrated). IgG deposits were frequently
observed in glomeruli of the two obese groups and increased with
age (Fig. 6 and Table 3). Acarbose significantly reduced the
frequency of these deposits. In lean rats, only a few glomeruli
showed such IgG deposits at early ages. However, the percentage
of IgG-positive glomeruli increased after 10 months and onwards.
Morphometric measurements, using an automated image anal-
ysis system, revealed that between 5 and 10 months the glomeruli,
glomerular tufts and glomerular urinary spaces increased in size,
slightly in ZL rats, and more intensively and rapidly in ZO and
ZOA rats (Fig. 7). After 10 months, a decline in the entire
glomerular surface area was observed in ZO rats, due to a large
reduction of the urinary space surface area seen at 15 months.
Acarbose did not change the hypertrophy of the glomerulus nor
the cumulative surface area of the capillary lumen sections, which
remained higher in ZO and ZOA than in ZL rats (not shown).
The mesangial domain expanded between 5 and 10 months, faster
in ZO than in ZL rats, then plateaued in both the ZO and ZL
groups (Fig. 8). At 10 to 15 months, it was 1.4-fold more expanded
Triglycerides giliter
ZL
ZO
ZOA
Cholesterol giliter
ZL
ZO
ZOA
Insulin p.C/mi
ZL
ZO
ZOA
Glucose glliter
ZL
ZO
ZOA
Abbreviations are: ZL, Zucker lean rats; ZO, Zucker obese rats; ZOA, Zucker acarbose-treated rats; ND, not determined. Numbers of rats are in
parentheses.
Age effect, P < 0.05
Overall group effect, ZL vs. ZO rats, P < 0.05
Overall group effect, ZL vs. ZOA rats, P < 0.05
"Overall group effect, ZO vs. ZOA rats, P < 0.05
"ZOA vs. ZO, P < 0.05 at a given age
'ZOA vs. ZL, P < 0.05 at a given age
t_ .;'J .ti
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Fig. 2. Age-related changes in proteinuria. Proteinuria developed mark-
edly in obese rats until 10 months, but was more rapid and intensive in ZO
than in ZOA rats and tended to stabilize thereafter. In lean rats, a faint
proteinuria appeared only in the oldest animals. The age group effect was
P < 0.05. There were at least 8 rats in each group (8 <N> 12). Symbols
are: (•, ZL) Zucker lean rats; (•, ZO) Zucker obese rats; (A, ZOA)
Zucker obese rats treated with acarbose.
in ZO than in ZL rat kidneys. In ZOA rats, the mesangial surface
area increased more slowly than in ZO group and at 10 months
reached the ZL rat mesangial surface area value (Fig. 8). It still
increased thereafter to reach, at 15 months, the value seen in ZO
rats. Electron microscopy showed that the GBM in ZL and ZOA
regularly thickened between five months and 15 months. In ZO
rats, this increase was rapid between 8 and 10 months and
thereafter slowed down (Fig. 8). At 15 months, GBM thickness
was similar in all groups. The Bowman's capsule basement
membrane became thicker with age, more in ZO than in ZOA and
ZL rat kidneys, being similar in ZOA and ZL rats at 15 months
(ZL, 1.68 0.81 j.tm, N = 7; ZO, 1.99 0.17 j.m, N = 7; ZOA,
1.52 0.07 j.tm, N = 7).
DISCUSSION
In this study, all animals (lean, obese, and acarbose-treated
obese rats) were fed a diet enriched with 10% sucrose to worsen
the establishement of the kidney lesions commonly seen in obese
Zucker rats and to appreciate, in a caricatural situation, a
potential effect of a drastic reduction of sugar consumption. On
the whole, sucrose supplementation induced glomerular and
tubulointerstitial lesions at earlier ages than they normally occur
in non-sucrose-supplemented rats, as shown in a preceding study
[81. In 15-month-old rats, however, lesions were similar to those
seen in obese rats fed a standard diet. In lean rats, sucrose
supplementation had no effect on the appearance and severity of
the lesions, which partly occurred at and after 10 months (Table 3
and [8]). After sucrose supplementation, plasma insulin level
profiles remained at a high, roughly constant level from 5 to 15
months in obese rats; in lean rats, it significantly increased after 10
months. Triglycerides, but not cholesterol, as well as systolic blood
pressure were higher in lean and obese rats as compared to the
values seen in rats fed a standard diet [8].
Acarbose is a competitive inhibitor of a-glucosidases including
sucrase, dextrinase, maltase and glucoamylase [25] and, conse-
quently, reduces post-prandial blood glucose increments. Other
nutrient intakes appeared normal, as no evidence of illness or
Fig. 3. Histological aspects of a 10-month-old obese rat kidney. Focal and
segmental glomerular hyalinosis as well as tubular and interstitial lesions
were commonly seen in obese rats. In close vicinity of sclerosed glomeruli
(arrow) and damaged tubules, which present tubular casts and cystic
formations (stars), mononuclear cells invaded areas of interstitial fibrosis
(open arrows). Bar = 50 .rm.
distress was ever observed by us and by others [26]. Despite the
fact that obese and acarbose-treated obese Zucker rats had
similar food consumption, acarbose significantly reduced the body
wt gain. This is probably a direct consequence of impaired glucose
intake, bringing a lesser charge on adipocytes [27] and a lower
concentration of lipids in the body composition [26]. However,
intestinal transit modifications, such as degradation of unab-
sorbed carbohydrates in the large bowel that elicits flatulence and
diarrhea in the first weeks of treatment [25, 28], have also
probably affected the body wt gain at early ages. The major effects
of acarbose up to 10 months were a reduction of proteinuria and
in the frequency and severity of glomerular (albumin droplets and
FSGH, immunoglobulin deposits) and tubulointerstitial lesions,
as well as a reduction of hypertriglyceridemia and hyperinsulin-
emia, as compared to non-treated obese rats. Thereafter, the
acarbose effects seemed to partly disappear.
Several mechanisms such as a reduction of either systemic
hypertension or plasma levels of glucose, insulin and/or triglycer-
ides could explain the beneficial effect of acarbose on the onset
and development of glomerular and tubulointerstitial lesions.
Although final body weight in rats is more a factor for longevity
and minimal kidney disease than food intake [29, 30], the reduc-
tion of body and kidney weight gains we observed in ZOA rats is
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Table 3. Histological parameters
Scoring of lesions arbitrary Units
ZL
ZO
ZOA
% Glomerular tuft retraction
ZL
ZO
ZOA
% Glomeruli with FSGH
ZL
ZO
ZOA
% Glomeruli with IgG deposits
ZL
ZO
ZOA
5 months
1.1 0.125 (10)
1.722 0.147 (9)
0.833 0.118 (9)
1.52 0.42 (8)
5.57 1.17 (8)
3.71 1.31 (9)
0.07 0.07 (8)
3.84 1.28 (8)
0.24 0.12 (9)C
6.3 6.3 (10)
37 5.14 (9)
17.22 8.78 (9)
1.182 0.205 (11)
2.417 0.135 (12)
1.583 0.203 (12)C
0.87 0.27 (10)
4.43 0.66 (12)
5.35 1.04 (ll)f
0.15 0.08 (10)
4.23 1.32 (12)
7.55 3.38 (!1)t
1.5 1.17(11)
33.14 6.83 (11)
37.08 7.38 (i2)f
1.625 0.227 (8)
2.875 0.263 (8)
1.75 0.341 (8)
5.1 0.62 (8)
16.68 2.98 (8)
6.48 1.07 (8)
2.28 0.58 (8)
17.85 3.36 (8)
9.78 2.61 (g)e.f
14.75 6.08 (8)
51.5 6.10 (8)
31 3.53 (7)
15 months
1.25 0.154 (l0yhC
3.333 0.316 (12y"
2.611 0.406 (9)at
3.05 0.42 (10)U.b.C
13.78 3.19 (12)
18.89 4.89 (9)f
0.71 0.19 (1O)a.
19.69 5.12 (l2)d
13.61 4.81 (9)a.f
43.3 7.73 (10)ah.C
56.73 5.62(1 iy'
47.5 8.37 (7)
likely a consequence of the modification of hormonal or metabolic
balance induced by acarbose, and not a direct cause of kidney
function and structure improvement.
It is interesting to note that the sucrose supplemented diet
increased the systemic blood pressure in both lean and obese rats,
the latter being hypertensive as early as five months. In animals
fed a standard diet, blood pressure slightly increased with age but
remained in a normal range (120 to 130 mm Hg), with no
difference between lean and obese rats [8]. It is therefore tempt-
ing to consider hypertension as a major factor involved in the
hypertrophy of the glomerulus and the development of diffuse
glomerulosclerosis and FSGH lesions seen in these sucrose-
supplemented obese Zucker rats. However, despite a reduction in
blood pressure at five months, acarbose had no effect on the
overall expansion of the different glomerular domains, as shown
by automated image analysis, apart from a reduction of the
mesangial domain expansion from 5 to 10 months. Moreover,
systemic blood pressure at five months was similar in ZL and
ZOA rats, whereas proteinuria and lesions already occurred in
ZOA rats. In fact, it was shown that glomerular hemodynamic
alterations play only a little role in the initiation of glomerular
injury in this strain of rats [31, 321. GC increases later on, as the
glomerular lesions progress [31]. Therefore, hypertension could
worsen the lesions, but is probably not a key factor in initiating
diffused glomerulosclerosis and FSGH lesions in these sucrose-
supplemented obese Zucker rats. Glomerular size stabilized after
10 months and began to decline thereafter in ZO rats. This
decline is not an artifact of measurements, as glomeruli showing
manifest glomerular tuft retraction or extensive FSGH were not
taken into account because glomerular structures were almost
indistinguishable in these cases. It is probably a result of an
impairment in the GFR, indirectly triggered by a general alter-
ation of the tubulointerstitial area, a phenomenon observed in
progressive renal diseases [reviewed in 33]. The fact that the
decline in glomerular size was less pronounced in ZOA, where
tubulointerstitial lesions were also less severe, strengthens this
hypothesis.
As high glucose levels are known to stimulate glomerular
endothelial, epithelial and mesangial cell activities [34] as well as
proximal tubular cells [35], one might wonder if the beneficial
effect of acarbose on the appearance and progression of kidney
lesions was not simply due to a reduction of available glucose
molecules at the level of the target cells. It is noteworthy that ZL,
ZO and ZOA rats remained euglycemic for the entire course of
the study, despite a constant supplementation of the diet with
10% sucrose; thus, high glucose concentration in blood plasma
cannot be held directly responsible for the kidney impairment
observed in this study. Although a direct action of glucose on
glomerular and/or tubular cells probably has to be ruled out in
non-treated obese Zucker rats, glucose uptake might favor the
formation and the accumulation of advanced glycation end-
products, which have been implicated in the pathogenesis of
several of the complications of aging and diabetes [reviewed in 36,
37]. In this respect, acarbose significantly reduced glycated henio-
globin in diabetic db/db mouse [38].
Obese rats show an insulin resistance of most of the tissues but
adipocytes [271. In order to compensate the excess of non-
processed glucose, ZO rats developed higher hyperinsulinemia as
compared to standard diet-fed obese animals [8]. By impeding
intestinal glucose absorption, acarbose significantly reduced the
stimulation of islets of Langherans and the production of insulin.
As compared to non-treated ZO rats, acarbose significantly
lowered plasma insulin levels up to 10 months. Thereafter,
insulinemia increased drastically by a factor of two. This was
probably due to the modification of the intestinal sugar absorption
we observed in older acarbose-treated obese Zucker rats [21]. We
8 months
Age
10 months
Abbreviations are: FSGH, focal and segmental glomerular hyalinosis; ZL, Zucker lean rats; ZO, Zucker obese rats; ZOA, Zucker acarbose-treated
obese rats. Numbers of rats are in parentheses.
a Age effect, P < 0.05h Overall group effect, ZL vs. ZO rats, P < 0.05
C Overall group effect, ZL vs. ZOA rats, P < 0.05
d Overall group effect, ZO vs. ZOA rats, P < 0.05
ZOA vs. ZO, P < 0.05 at a given age
ZOA vs. ZL, P < 0.05 at a given age
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Fig. 4. Electron micrograph of a 10.month-old obese rat glomerulus.
Bulging of podocytes, in which numerous droplets accumulated (open
arrows), forestalled the establishment of FSGH lesions. In localized areas,
podocyte foot processes progressively detached from the glomerular
basement membrane (arrow). Bar = 2.5 jm.
showed that, in ZOA rats, the jejunal length increased with the
duration of acarbose treatment, resulting in an increase of the
total number of Na/D-glucose co-transporters, able to compen-
sate in part for the reduction of glucose uptake. In ileum, the
capacity of the sucrase, which at five months was twofold lower in
the ileum than in the jejunum, at 15 months increased to reach the
value seen in the jejunum. The sucrase affinity for acarbose
diminished in the jejunum with age [39]. Therefore, a prolonged
administration of acarbose results in an intestinal adaptation and
in a reduction of the effect of the drug, as already proposed [401.
The level of the intestinal adaptation for sucrase activity and
glucose uptake was on the same range as the increase of plasma
insulin we observed in this study, and might explain the absence of
the protective effect of acarbose after 10 months. In vitro, insulin
stimulates mesangial cell activity [41—441, probably through its
activation of the insulin-like growth factor-I (IGF-I) receptor [45].
Both IGF-I and growth hormone have been shown to be poten-
tially important factors in the development of glomerulosclerosis
[46, 47]. It is likely that, in vivo, insulin might also activate
mesangial cells, either directly or through pathways involving
other growth factors and cytokines, such as TGF-f31 [44]. Unless
insulin has a direct effect on tubular and interstitial cells, tubular
alterations are more probably the result of the alteration of the
Fig. 5. Electron micrograph of a 10-month-old obese rat glomerulus
showing a typical appearance of a FSGH lesion. Podocyte foot processes
progressively detached from the glomerular basement membrane (arrow),
with newly synthesized ECM components accumulating in the formed
interspace. Denuded parts of glomerular basement membrane (gbm)
constituted foci of adherence with the basement lamina of Bowman's
capsule (Bbm). Underlying capillaries collapsed with a progressive disap-
pearance of endocapillary cells and a formation of hyalin (H) and lipid (L)
deposits. Bar = 2.5 pm.
glomerular filtration barrier and of the ensuing proteinuria [re-
viewed in 48]. Proximal tubular cells become rapidly clogged with
lysosomes of endocytosed proteins, and in the intercellular me-
dium release inflammatory molecules and cellular debris, which in
turn induce interstitial inflammation and fibrosis [49—52]. It is
noteworthy that in this study, proteinuria preceded, or was
concomitant with, tubular alterations. As seen on kidney sections
of ZO and, to a lesser extent, ZOA rats, the interstitial inflam-
mation and fibrosis area, tubular lesions and casts, and glomeruli
with FSGH lesions most of the time were colocalized. Acarbose
significantly reduced the plasma levels of insulin in ZOA rats and,
concomitantly, the incidence of proteinuria and the severity of
glomerular, tubular and interstitial lesions. Therefore, hyperinsu-
linemia, which is observed in normally-fed obese Zucker rats as
soon as weaning [6, 8], appears to be a key factor to trigger renal
fibrosis.
Hyperlipidemia is another potent candidate in initiating kidney
dysfunction. Low and very low density lipoproteins (LDL and
VLDL, respectively) directly stimulate mesangial cells in vitro. In
turn, mesangial cells produce superoxide anions that oxidize LDL
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Fig. 6. Immunodetection of albumin and IgG deposits in 8-month-old lean A, D), obese (B, B) and acarbose-treated obese (C, F) Zucker rat
glomerulus. Albumin (A, B, C), in characteristic droplets in podocytes, and lgG (D, E, F), in mesangial deposits, accumulated more in obese than in
acarbose treated-rats. No or very few deposits were seen in the lean rats. Bar = 25 jsm.
and VLDL, whose atherogenicity is then dramatically increased
[reviewed in 1, 2]. This mechanism probably occurs in this strain
of rats at early ages as the obese Zucker rats rapidly develop
hyperlipidemia [6, 91 long before a renal impairment is detected
[8, 9]. By lowering glucose uptake, acarbose significantly reduced
plasma levels of triglycerides, which were twofold lower in ZOA
than in ZO rats at five months, an age where proteinuria, diffuse
glomerulosclerosis (mesangial matrix and GBM expansion) and
FSGH lesions were already pronounced in ZO and reduced in
ZOA. This reduction of plasma triglycerides is either a direct
consequence of a lack of fuel to triglyceride synthesis or due to a
reduction of the level of insulin, implicated in the triglyceride
synthesis pathway, which reduces VLDL-triglyceride production
by the liver [53]. Reduction of VLDL production could also
explain the decrease in cholesterolemia seen at 10 and 15 months.
Kasiske et al [17] found that lowering of serum cholesterol by
mevilonin in Zucker rats was more important than the decline in
serum triglycerides by clofibric acid in ameliorating the glomeru-
lar lesions. However, acarbose reduced cholesterolcmia only at 10
months and later, whereas it already had a beneficial effect on
1540 Michel et al. Insulin, triglycerides and glomeruloscierosis
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Fig. 7. Morphometric measurements of the glomerular domains in lean(, ZL), obese (•, ZO) and acarbose-treated obese (A, ZO) Zucker rat
glomeruli. The entire glomerulus (A) and the glomerular tuft (B) in-
creased in size with age in both obese and lean rats (age effect, P < 0.001
for both parameters), but was greater in obese than in lean rats (ZL vs. ZO
and ZOA rats, P < 0.001). After 10 months, a decline in the whole
glomerular surface area was observed in the obese groups, slight in ZOA,
pronounced in ZO rats, mainly due, in ZO rats, to a large reduction of the
urinary space surface area (C) seen at 15 months. N = 7 rats/group.
kidney evolution as early as five months. This indicates that
control of renal impairment by acarbose involves mechanisms in
which cholesterol has only a small role, at least during the early
ages of development. Altogether, from our data it is difficult to
make a firm conclusion on the specific and relative roles of both
insulin and triglycerides on the onset and progression of kidney
disease in obese Zucker rats, since insulin is implicated in the
triglyceride pathway itself.
In summary, the blockade of intestinal glucose uptake by
acarbose significantly reduced the incidence of renal insufficiency
and the severity of FSGH and tubulointerstitial alterations that
rapidly develop in obese Zueker rats. This beneficial effect was
not due to a reduction of plasma glucose concentration as these
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Fig. 8. Morphometric measurements of the extracellular matrices expan-
sion in lean (, ZL), obese (•, ZO) and acarbose-treated obese (A, ZOA)
Zucker rat glomeruli. (A) The mesangial domain expanded faster in ZO
than in ZL rats between 5 and 10 months, and then plateaued in both ZO
and ZL groups. In ZOA rats, the mesangial surface area increase was
regular but slower than in ZO group, at 15 months reaching the value seen
in ZO rats (age and group effects, P < 0.05). Electron microscopy
measurements showed that the GBM regularly thickened between five
months and 15 months, in ZL and ZOA. In ZO rats, this increase was
faster between 8 and 10 months and slowed down thereafter (age effect,
P < 0.05). N = 7 rats/group.
animals, which present an insulin resistance comparable to that
seen in Type II diabetes, were still able to control their glycemia,
even when they were fed a sucrose-supplemented diet. However,
the maintenance of glucose levels is achieved at a higher expense
of insulin. In blocking the glucose uptake, acarbose significantly
reduced the levels of insulin and triglycerides, both factors that
are directly implicated in the pathogenesis of kidney lesions.
Therefore, acarbose appears to be of potential interest to reduce
renal dysfunction complications in Type II diabetic patients,
either alone, or in association with other therapies [54].
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